Cargando…

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive disease without standardized treatment strategies. The efficacy of second-line or beyond immune checkpoint inhibitors (ICIs) has been proven in recent studies, whereas the evidence for first-line immunotherapy for PSC is stil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Zhimin, Qian, Xiaoying, Liu, Fanrong, Wang, Yong, Yuan, Yong, Fang, Chen, Zhang, Xinwei, Yuan, Shangkun, Chen, Renfang, Yu, Biao, Wang, Tong, Yin, Yan, Li, Yong, Liu, Anwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659892/ https://www.ncbi.nlm.nih.gov/pubmed/36389780 http://dx.doi.org/10.3389/fimmu.2022.956982

Ejemplares similares

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

Neutrophil Extracellular Traps (NETs) Promote Non-Small Cell Lung Cancer Metastasis by Suppressing lncRNA MIR503HG to Activate the NF-κB/NLRP3 Inflammasome Pathway
por: Wang, Yong, et al.
Publicado: (2022)

Pan-cancer analysis of the FAM83 family and its association with prognosis and tumor microenvironment
por: Yuan, Shangkun, et al.
Publicado: (2022)

Immunophenotyping of pulmonary sarcomatoid carcinoma
por: Ma, Yu, et al.
Publicado: (2022)

A innovative prognostic symbol based on neutrophil extracellular traps (NETs)-related lncRNA signature in non-small-cell lung cancer
por: Fang, Chen, et al.
Publicado: (2021)

rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy
por: Wang, Yong, et al.
Publicado: (2022)

Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma
por: Xu, Wenhao, et al.
Publicado: (2022)

Recurrence of pulmonary sarcomatoid carcinoma presenting as haemothorax: a case report
por: Su, Chen, et al.
Publicado: (2023)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting System database
por: Liu, Yunwei, et al.
Publicado: (2022)

Pulmonary sarcomatoid carcinoma: a case report
por: Shen, Xiao-yong, et al.
Publicado: (2013)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Sarcomatoid Intrahepatic Cholangiocarcinoma After Immunotherapy: A Case Report and Review of the Literature
por: Zeng, Zheng, et al.
Publicado: (2022)

Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review
por: Wu, Shugui, et al.
Publicado: (2023)

Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma
por: Wang, Zhixian, et al.
Publicado: (2018)

Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
por: Wei, Fuqun, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice
por: Inomata, Minehiko, et al.
Publicado: (2023)

PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
por: Gao, Yuan, et al.
Publicado: (2022)

Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
por: Brockwell, Natasha K., et al.
Publicado: (2020)

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations
por: Li, Xin, et al.
Publicado: (2020)

Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China
por: Che, Kaijun, et al.
Publicado: (2023)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023)

Factors influencing immunogenicity and safety of SARS-CoV-2 vaccine in liver transplantation recipients: a systematic review and meta-analysis
por: Luo, Xinyi, et al.
Publicado: (2023)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Sarcomatoid carcinoma of colon: extremely poor prognosis
por: Choi, Yoon Young, et al.
Publicado: (2011)

Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection
por: Zheng, Meijun, et al.
Publicado: (2023)

Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers
por: Chen, Xian, et al.
Publicado: (2022)

Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma
por: Sim, Jae Kyeom, et al.
Publicado: (2018)

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study
por: Liu, Xue-wen, et al.
Publicado: (2020)

MET alterations in advanced pulmonary sarcomatoid carcinoma
por: Gong, Chen, et al.
Publicado: (2022)

Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
por: Zhang, Xuan, et al.
Publicado: (2022)

Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Shen, Jinhai, et al.
Publicado: (2023)

Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
por: Guo, Xinyu, et al.
Publicado: (2023)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yan, Yi-Dan, et al.
Publicado: (2021)

A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
por: Zhou, Xiaohan, et al.
Publicado: (2021)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
por: Sharma, Rohini, et al.
Publicado: (2021)

Clinical Significance and Next-Generation Sequencing of Chinese Pulmonary Sarcomatoid Carcinoma
por: Li, Xin, et al.
Publicado: (2017)

Severe Hypoglycemia Caused by Recurrent Sarcomatoid Carcinoma in the Pelvic Cavity: A Case Report
por: Fang, Chao, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lml96latbcvqp68ij0re8h77j6